Health Sciences Group, Inc. (HESG)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Health Sciences Group, Inc. (HESG) trades at $0.00 with AI Score 60/100 (Grade B+). Health Sciences Group, Inc. operates in the nutritional supplements and functional foods sector, offering products like sugar substitutes and cardiovascular health formulas. Market cap: $1.87M, Sector: Healthcare.
Price live · AI analysis from Mar 15, 2026Analyst Coverage for HESG: HESG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HESG against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
HESG: 2/4 perspectives are bearish. Dominant signal: Moon AI bearish.
How is this calculated? →Health Sciences Group, Inc. (HESG) Healthcare & Pipeline Overview
Health Sciences Group, Inc. develops and distributes nutritional supplements and functional food products, including sugar substitutes and cardiovascular health formulas, primarily through mass market retailers and healthcare professionals. Facing a competitive landscape in the biotechnology sector, the company focuses on proprietary blends and unique product offerings within the United States.
What Is the Investment Thesis for HESG?
Health Sciences Group, Inc. faces significant challenges given its small market capitalization and negative profitability. With a market cap of $1.87M and a negative P/E ratio, the company's financial stability is uncertain. The company's gross margin of 7.0% and profit margin of -15.2% indicate operational inefficiencies. The high beta of 2.74 suggests high volatility relative to the market. Growth prospects hinge on successful product commercialization and expansion into new markets, but these are speculative. Investors should carefully consider the risks associated with investing in a micro-cap company with limited resources and negative earnings.
Based on FMP financials and quantitative analysis
HESG Key Highlights
- Market capitalization of $1.87M indicates the company's small size and potential liquidity concerns.
- Negative P/E ratio reflects the company's lack of profitability.
- Gross margin of 7.0% suggests challenges in maintaining competitive pricing and managing production costs.
- Profit margin of -15.2% highlights the company's struggle to achieve profitability.
- Beta of 2.74 indicates high volatility compared to the overall market.
Who Are HESG's Competitors?
HESG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADXS Ayala Pharmaceuticals, Inc. | $0.60 | +0.00% | $25.71M | 43 |
| GRTX Galera Therapeutics, Inc. | $0.09 | -3.72% | $6.69M | 50 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HESG's Key Strengths?
- Proprietary product formulations.
- Established distribution network.
- Brand recognition for specific products.
- Focus on specific health and wellness niches.
What Are HESG's Weaknesses?
- Small market capitalization.
- Limited financial resources.
- Negative profitability.
- Dependence on a limited number of products.
What Could Drive HESG Stock Higher?
- Potential new partnerships with healthcare providers to expand distribution.
- Launch of new product lines targeting specific health concerns.
- Efforts to increase brand awareness through digital marketing campaigns.
What Are the Key Risks for HESG?
- Financial-distress signal — its Altman Z-Score of -15.94 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger, more established companies.
- Changing consumer preferences and health trends.
- Regulatory changes affecting the nutritional supplement industry.
- Limited financial resources and negative profitability.
- Risks associated with trading on the OTC market.
What Are the Growth Opportunities for HESG?
- Expansion into E-commerce Channels: Health Sciences Group can leverage the growing e-commerce market to reach a broader customer base. The global e-commerce market is projected to reach trillions of dollars by 2026, offering a significant opportunity for direct-to-consumer sales. Investing in a robust online platform and digital marketing strategies could drive revenue growth and brand awareness.
- Strategic Partnerships with Healthcare Providers: Collaborating with healthcare professionals and practitioners can enhance the credibility and adoption of Health Sciences Group's products. By establishing partnerships with clinics, hospitals, and wellness centers, the company can gain access to a targeted audience and leverage the influence of healthcare providers to promote its offerings. This approach can be particularly effective for products like Sequesterol Advance Cardio Formula.
- Development of New Product Lines: Expanding the product portfolio to include additional nutritional supplements and functional foods can cater to a wider range of consumer needs and preferences. Researching emerging health trends and developing innovative products that address specific health concerns can drive revenue growth and market share. This includes exploring opportunities in areas such as immune support, digestive health, and cognitive function.
- Geographic Expansion into International Markets: Entering new geographic markets can unlock significant growth potential for Health Sciences Group. Conducting market research to identify regions with strong demand for nutritional supplements and functional foods can inform strategic expansion plans. Adapting product formulations and marketing strategies to suit local preferences and regulatory requirements is crucial for success.
- Focus on Clinical Research and Validation: Investing in clinical research to validate the efficacy and safety of Health Sciences Group's products can enhance their credibility and appeal to consumers and healthcare professionals. Conducting clinical trials and publishing research findings in peer-reviewed journals can provide scientific evidence to support product claims and differentiate the company from competitors. This approach can be particularly valuable for products like Sequesterol Advance Cardio Formula.
What Opportunities Does HESG Have?
- Expansion into e-commerce channels.
- Strategic partnerships with healthcare providers.
- Development of new product lines.
- Geographic expansion into international markets.
What Threats Does HESG Face?
- Intense competition from larger companies.
- Changing consumer preferences.
- Regulatory changes.
- Economic downturns.
What Are HESG's Competitive Advantages?
- Proprietary product formulations (e.g., Sequesterol Advance Cardio Formula).
- Established distribution network through mass market retailers.
- Brand recognition for specific products like Shugr.
What Does HESG Do?
Health Sciences Group Inc., established in 1996 as Centurion Properties Development Corporation, has evolved into a provider of nutritional supplements and functional foods. Initially focused on real estate development, the company transitioned to the health and wellness sector, rebranding as iGoHealthy.com in 2000 before adopting its current name in 2001. The company's core offerings include Shugr, a zero-calorie sugar substitute designed to mimic the taste and baking properties of cane sugar, and Sequesterol Advance Cardio Formula, a proprietary blend of ingredients aimed at supporting cardiovascular health. Additionally, Health Sciences Group offers Aplevia, an antioxidant derived from apple peels, and Edible Sponges, an open-cell hydrocolloid product. These products are distributed through a network of mass market retailers, including mass merchandisers, drug stores, supermarkets, and discount stores, as well as through healthcare professionals and practitioners. Headquartered in Newport Beach, California, Health Sciences Group operates primarily within the United States, navigating a competitive market landscape to establish its presence in the nutritional supplements and functional foods industry.
What Products and Services Does HESG Offer?
- Develops and markets zero-calorie sugar substitutes.
- Offers cardiovascular health supplements.
- Provides antioxidant products derived from apple peels.
- Manufactures edible hydrocolloid products.
- Distributes products through mass market retailers.
- Sells products through healthcare professionals and practitioners.
How Does HESG Make Money?
- Develops and manufactures nutritional supplements and functional foods.
- Sells products through mass market retailers and healthcare professionals.
- Generates revenue through product sales.
What Industry Does HESG Operate In?
Health Sciences Group operates in the competitive biotechnology industry, specifically within the nutritional supplements and functional foods market. This market is characterized by increasing consumer interest in health and wellness, driving demand for innovative products like sugar substitutes and cardiovascular health supplements. However, the industry is also highly regulated and subject to intense competition from larger, more established players. Health Sciences Group's success depends on its ability to differentiate its products, effectively market to consumers, and navigate the complex regulatory landscape.
Who Are HESG's Key Customers?
- Consumers seeking sugar substitutes.
- Individuals looking for cardiovascular health support.
- Healthcare professionals recommending supplements to patients.
ROE 3%Key Financial Metrics
Return on equity for Health Sciences Group, Inc. stands at 2.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.3%, showing how much profit it generates from its asset base. Its free cash flow yield is 2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.31 means current liabilities exceed short-term assets, a liquidity point worth watching.
Health Sciences Group, Inc. (HESG) Valuation Context
Valued at $1.87M, HESG is classified as a micro-cap stock. Relative to its peer group, HESG's quantitative score of 60/100 is roughly in line with the peer average of 65/100.
Company Profile
Health Sciences Group, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Newport Beach, US. The company is led by CEO Thomas Gaffney. HESG has traded publicly since 2001.
F-Score 2/9Financial Health
Health Sciences Group, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.94 places it in the distress zone, a signal of elevated financial risk.
HESG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that executives believe in the growth potential of Health Sciences Group.
- Community sentiment has shifted positively, with increased discussions around the company's innovative health solutions resonating with investors.
- The company's recent partnerships in the healthcare sector have generated excitement, showcasing their commitment to expanding their market reach.
- Market perception is leaning towards optimism as Health Sciences Group continues to enhance its product offerings, aligning with current health trends.
Bear Case
- Despite recent positive sentiment, some analysts express concerns over the company's ability to scale operations effectively, given the competitive landscape.
- Recent discussions in the community highlight skepticism regarding the sustainability of its revenue streams, with some questioning long-term viability.
- There are worries around regulatory challenges that could impact the company's growth, as healthcare regulations continue to evolve.
- Market perception reflects caution, with some investors wary of the volatility in the healthcare sector, which could affect Health Sciences Group's performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HESG Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
-
Stocks That Hit 52-Week Lows On Tuesday
· Feb 4, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Jan 17, 2020
-
Stocks That Hit 52-Week Lows On Thursday
· Jan 9, 2020
HESG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HESG.
Price Targets
Wall Street price target analysis for HESG.
HESG MoonshotScore
What does this score mean?
The MoonshotScore rates HESG's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Thomas Gaffney
CEO
Thomas Gaffney serves as the CEO of Health Sciences Group, Inc. Information regarding his detailed career history and educational background is not available in the provided data. As CEO, he is responsible for the overall strategic direction and operational management of the company, overseeing the development, marketing, and distribution of its nutritional supplements and functional food products. He manages a small team of 2 employees.
Track Record: Given the limited information available, it is difficult to assess Thomas Gaffney's specific achievements and strategic decisions as CEO. The company's financial performance, characterized by negative profitability and a small market capitalization, suggests significant challenges. Further information is needed to evaluate his track record effectively.
HESG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Health Sciences Group, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Longevity of the company's operations (founded in 1996).
- Presence of established products (e.g., Shugr, Sequesterol).
- Distribution through mass market retailers.
- Physical headquarters in Newport Beach, California.
What Investors Ask About Health Sciences Group, Inc. (HESG) — Healthcare
What does Health Sciences Group, Inc. do?
Health Sciences Group, Inc. develops, markets, and distributes nutritional supplements and functional food products. Its primary offerings include Shugr, a zero-calorie sugar substitute, and Sequesterol Advance Cardio Formula, a cardiovascular health supplement. The company distributes its products through mass market retailers and healthcare professionals, targeting consumers seeking health and wellness solutions. The company also offers Aplevia, an antioxidant derived from apple peels, and Edible Sponges, an open-cell hydrocolloid product.
What do analysts say about HESG stock?
As of 2026-03-15, formal analyst ratings for Health Sciences Group, Inc. (HESG) are unavailable, likely due to its small market capitalization and OTC listing. Key valuation metrics such as P/E ratio are not meaningful given the company's negative earnings. Growth considerations would depend on successful product commercialization and expansion, but these are highly speculative. Investors should conduct their own thorough due diligence.
What are the main risks for HESG?
Health Sciences Group, Inc. faces several key risks. These include intense competition in the nutritional supplement industry, the risk of changing consumer preferences, potential regulatory changes, limited financial resources, and the inherent risks associated with trading on the OTC market. The company's negative profitability and small market capitalization further amplify these risks.
What are the key factors to evaluate for HESG?
Health Sciences Group, Inc. (HESG) holds an AI score of 60/100 (moderate). Not financial advice.
How frequently does HESG data refresh on this page?
HESG prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HESG's recent stock price performance?
Health Sciences Group, Inc. (HESG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary product formulations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HESG overvalued or undervalued right now?
Valuing Health Sciences Group, Inc. (HESG) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying HESG?
Before investing in Health Sciences Group, Inc. (HESG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for comprehensive analysis.
- OTC market investments carry higher risks.